TKT and cancer: In HeLa and SiHa cisplatin-resistant cells, the miR-497 downregulation ensures high levels of TKT which ultimately provides cancer cells with GSH to counteract the cisplatin-induced ROS-derived cytotoxicity [43] (Table 1 and Figure 2).